On the evening of August 26th, the news of Jiahui Medical suspending the vaccination of Sanofi's Pasteur influenza vaccine spread online, involving trivalent and quadrivalent products.
On August 27th, Sanofi told a reporter from Beike Finance of the New Beijing News that the influenza vaccine products themselves are highly complex due to the suspension of influenza vaccination. During the ongoing stability assessment by Sanofi, it was observed that the potency of the influenza vaccines Valin and Valga during the 2024-2025 influenza season (relevant reference data for the expected biological effects of the vaccines) showed a decreasing trend. The company expects that the efficacy of the vaccine may be affected before the end of the product's shelf life. As a preventive measure, Sanofi has decided to temporarily suspend the supply and sale of these vaccines in China.
Sanofi also stated that the influenza vaccines Valin and Valga, which have been launched and circulated this year, have been approved for marketing and strictly comply with various laws and regulations, national drug standards, and legal requirements, meeting the release standards. No signs or evidence have been found to affect the safety and effectiveness of the product. The decision to temporarily suspend the supply and sale of these vaccines in China is only a preventive measure.